Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma

NCT05627960 is registered in ClinicalTrials.gov with A&G Pharmaceutical Inc. as lead sponsor.

NCT NCT05627960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05627960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
Lead sponsor
A&G Pharmaceutical Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 14, 2022
Completion date
November 30, 2026
Enrollment
77 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-resistant breast cancer, mesothelioma, non small cell lung cancer, triple negative breast cancer